1 hr ago
Follow The Money
Last night, there was an article on Bloomberg highlighting how American Mutual Funds were scouring Europe for bargains.
Wed Dec 11, 2013
Novartis: 2 Novel Cancer Therapies Show Promising Results
The giant Swiss multinational healthcare company Novartis has seen its stock rise almost 25% YTD, and while it will lose revenue due to patent expiration on three of its most profitable drugs, including Glivec, Zometa and - new drugs working through the pipeline should make up for much of the lost revenue.
Tue Dec 10, 2013
VEA, KRU: Big ETF Inflows
Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF , which added 3 million units, or a 0.7% increase week over week.
Wall Street Breakfast: Must-Know News
Top Stories Treasury exits rest of GM stake and makes loss of $10.5B. The government has sold the remainder of its 31.1M shares in GM for $9.2B, which will end restrictions on executive pay and could pave the way for dividends and buybacks.
Sun Dec 08, 2013
Health Canada Approves Bexsero*, the First Vaccine Available to...
Bexsero* is indicated to help protect individuals from two months through 17 years of age against meningococcal B disease, including infants, children one to four years and adolescents who are at the greatest risk of infection2,3 4 .
Novartis CEO says can spend $4-6 bln a year on buys -paper
Swiss drugmaker Novartis can spend $4-6 billion per year on acquisitions to strengthen its core pharma, eyecare and generics businesses or its three smaller units, its chief executive officer said in an interview on Sunday.
Sat Dec 07, 2013
CARs show promise in treating blood cancer
Technology now licensed to Novartis for clinical testing is showing promise in the treatment of blood cancer, studies outlined at ASH show.
Fri Dec 06, 2013
Pfizer - Key Reasons to Long This Biopharmaceutical Giant
Pfizer is one of the biopharmaceutical companies hardest hit by drugs losing patent exclusivity.
Novartis Investigational Compound LBH589 Met Primary Endpoint in Phase III Study
Novartis today announced that results of a Phase III trial of the investigational compound LBH589 in combination with bortezomib and dexamethasone, met the primary endpoint of significantly extending progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma when compared to bortezomib plus dexamethasone alone.
Thu Dec 05, 2013
A Bull/Bear Outline For The Unilife Debate
In our previous article on Unilife , published on November 27th 2013, we predicted that UNIS would probably break 100% in YTD gains.
Novartis Africa Day Highlights Company's Efforts to Expand Access to Healthcare
"Novartis is taking an outcomes approach, looking beyond therapeutic solutions to a focus on new technologies, new commercial models, education and training," says Joseph Jimenez, Chief Executive Officer of Novartis, who will open the event.
Wed Dec 04, 2013
Unilife: A Look At The Novartis News
On Monday night, after markets were closed, Unilife Corp announced an agreement with Novartis to supply clinical products from one of its platforms of injectable drug delivery systems for use with one of Novartis' targeted early-stage pipeline drugs.
Stocks to Watch: Unilife Corp
Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages.
Tue Dec 03, 2013
Supply Deal Leads Unilife Corp (UNIS) to New High
Under the deal's terms, UNIS will provide a customized delivery device for one of NVS' early stage pipeline drugs.
RDInvesting Provides Investors with Free In-Depth Equity Reports on...
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events.
Mon Dec 02, 2013
Glivec Generics May Be Delayed In The U.S. - Buy Novartis
Glivec which is prescribed for the treatment of Ph+ chronic myeloid leukemia is one of the most profitable drug in Novartis marketed drug portfolio.
Sun Dec 01, 2013
Buy Novartis For A Safe And Growing Income
Novartis is a Swiss multinational pharmaceutical company, ranking among the largest companies among the worldwide industry by sales.
Fri Nov 29, 2013
Novus Energy Inc. announces third quarter 2013 results
These may be accessed through the SEDAR website www.sedar.com under the Company's profile and at the Company's website www.novusenergy.ca .
Thu Nov 28, 2013
Novartis Foundation launches new leprosy strategy at symposium on disease elimination
Novartis International AG /Novartis Foundation launches new leprosy strategy at symposium on disease elimination .
Sun Nov 24, 2013
Swiss Voters Reject Strict CEO Pay Limits in Referendum
Swiss voters rejected a proposal to limit executives' pay to 12 times that of junior employees, a measure that would have gone further than any other developed nation.